William C. Huang, MD
Preliminary findings from an ongoing study have demonstrated efficacy and quality-of-life benefits associated with robotic-assisted cystectomy in patients with muscle-invasive bladder cancer, pointing to a potential shift in current practice.
The ongoing randomized phase III RAZOR trial is comparing open radical cystectomy (ORC) with robotic-assisted radial cystectomy (RARC) in patients with stage T1-T4, N0-N1, M0 bladder cancer. The study has a noninferiority endpoint, as well as blood transfusion rate, estimated blood loss, length of stay, complications, lymph node yield, and margin status.
... to read the full story